Advertisement

Topics

The Pulmonary Fibrosis Foundation Company Profile

06:54 EST 19th December 2018 | BioPortfolio

The Pulmonary Fibrosis Foundation is 501©(3) organization, whose mission is to find a cure for idiopathic pulmonary fibrosis (IPF) by funding research, advocating for IPF issues, promoting disease awareness, and providing a compassionate environment for supporting patients and their loved ones. We achieve these goals by promoting new research through increased funding; by representing the needs of our constituents in Washington DC through national advocacy; and by developing caring relationships with patients and their families throughout the course of their disease. To date the PFF has funded more than $2.7 million in IPF research. For more information, please visit www.pulmonaryfibrosis.org, email us at info@pulmonaryfibrosis.org, or call 888-PFF-ORG1 (888) 733-6741.


News Articles [1204 Associated News Articles listed on BioPortfolio]

Galectin Therapeutics Receives Patent for GR-MD-02 Patent for Method and Treatment of Pulmonary Fibrosis

Galectin Therapeutics (NASDAQ:GALT) the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the Company has received notice of issuance o...

Experimental findings support a connection between mucins in the lung and pulmonary fibrosis

A team of investigators has identified a connection between mucus in the small airways and pulmonary fibrosis.

Aridis Expands Research Agreement with the Cystic Fibrosis Foundation and is Awarded FDA ...

SAN JOSE, Calif., Dec. 4, 2018 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced that the Cystic Fibrosis Foundation (CF Foundation) has more than Read more...

New guideline aids in diagnosing idiopathic pulmonary fibrosis

(American Thoracic Society) A new international guideline has been developed to help physicians diagnosis idiopathic pulmonary fibrosis (IPF), a rare and often fatal lung disease whose cause is unknow...

Exacerbation management

With backing from the Cystic Fibrosis Foundation, Corbus and Celtaxsys will be the first companies to seek approval in CF based on pulmonary exacerbations instead of FEV1.

Idiopathic Pulmonary Fibrosis (IPF) Market Insights, Epidemiology and Market Forecast to 2027 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Idiopathic Pulmonary Fibrosis (IPF) – Market Insights, Epidemiology and Market Forecast-2027” report has been added to ResearchAndMarkets.com&...

FDA fast-tracks FibroGen's idiopathic pulmonary fibrosis therapy

FibroGen's pamrevlumab, being developed to treat patients with idiopathic pulmonary fibrosis, was granted fast-track designat -More- 

Anti-Reflux Surgery Promising in Idiopathic Pulmonary Fibrosis

MONDAY, Oct. 1, 2018 -- Laparoscopic antireflux surgery is safe and well-tolerated in patients with idiopathic pulmonary fibrosis (IPF) and abnormal acid gastroesophageal reflux (GER), according to a ...

Drugs and Medications [486 Associated Drugs and Medications listed on BioPortfolio]

Esika [Ventura Corporation (San Juan, P.R)]

ēsika 3-in-1 Pro Make Up Foundation SPF 20

Sheer cover mineral foundation [Guthy-Renker LLC]

Sheer Cover Mineral Foundation SPF-15

Cle de peau beaute silky foundation i [SHISEIDO CO., LTD.]

CPB Silky Cream Foundation I

Cle de peau beaute foundation i [SHISEIDO CO., LTD.]

cle de peau BEAUTE Cream Foundation I

Shiseido perfect refining foundation [SHISEIDO AMERICA INC.]

SHISEIDO Perfect Refining Foundation

PubMed Articles [2519 Associated PubMed Articles listed on BioPortfolio]

Antineutrophil Cytoplasmic Antibody-Associated Lung Fibrosis.

Pulmonary fibrosis is observed in a substantial number of patients with ANCA-associated vasculitis (AAV), 15% in a recent German series, and may be more frequent in Asian populations. ANCA are usually...

Dihydroartemisinin alleviates oxidative stress in bleomycin-induced pulmonary fibrosis.

Dihydroartemisinin has been shown to inhibit the development of pulmonary fibrosis in rats, but its mechanism has yet to be elucidated. This study aimed to determine the mechanisms of dihydroartemisin...

A Novel Variant of Desmoplakin Is Potentially Associated with Silicosis Risk.

Two genome-wide association studies and one sequencing study have coincidently reported significant associations of single nucleotide polymorphisms (SNPs) in the desmoplakin (DSP) gene with the risk o...

A case report of heterozygous TINF2 gene mutation associated with pulmonary fibrosis in a patient with dyskeratosis congenita.

Dyskeratosis congenita (DC) is a rare inherited disease characterized by the classical mucocutaneous triad. Pulmonary fibrosis, bone marrow failure, and solid tumors are the main causes of mortality i...

Prodigiosin Alleviates Pulmonary Fibrosis Through Inhibiting miRNA-410 and TGF-β1/ADAMTS-1 Signaling Pathway.

Pulmonary fibrosis is a common outcome of various interstitial lung diseases. Prodigiosin (PG) is a series of red pigment with methoxypyrrole ring. This studyinvestigates therole of prodigiosin in pul...

Clinical Trials [4579 Associated Clinical Trials listed on BioPortfolio]

A Linkage and Association Study in Pulmonary Fibrosis

The purpose of this study is to investigate inherited genetic factors that play a role in the development of familial pulmonary fibrosis and to identify a group of genes that predispose in...

Standardized Treatment of Pulmonary Exacerbations II

Cystic fibrosis (CF), a life-shortening genetic disease, is marked by acute episodes during which symptoms of lung infection increase and lung function decreases. These pulmonary exacerbat...

Pirfenidone for the Treatment of Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis (PF/IPF)

To assess the long-term safety and efficacy of oral pirfenidone in doses of up to 40 mg/kg/d in a limited number of patients with pulmonary fibrosis/idiopathic pulmonary fibrosis (PF/IPF)

Effects of Pulmonary Rehabilitation on Functional and Health Status Measures in Pulmonary Fibrosis

The inclusion of Pulmonary Rehabilitation (PR) as part of the management of pulmonary fibrosis although being highly recommended and recommended in guidelines still sees studies exploring ...

Microarray Analysis of Gene Expression in Idiopathic Pulmonary Fibrosis (IPF)

This study is investigating the way the lung is damaged in a condition called pulmonary fibrosis. Research studies will be conducted on lung tissue obtained from an open lung biopsy perfo...

Companies [1574 Associated Companies listed on BioPortfolio]

The Pulmonary Fibrosis Foundation

The Pulmonary Fibrosis Foundation is 501©(3) organization, whose mission is to find a cure for idiopathic pulmonary fibrosis (IPF) by funding research, advocating for IPF issues, promoting disease aw...

Coalition for Pulmonary Fibrosis

Pulmonary Fibrosis (PF) is a lung disorder characterized by a progressive scarring - known as fibrosis -- and deterioration of the lungs, which slowly robs its victims of their ability to breathe. App...

Cystic Fibrosis Foundation

The Cystic Fibrosis Foundation is the world's leader in the search for a cure for cystic fibrosis. The Foundation funds more CF research than any other organization and nearly every CF drug available ...

New Lung Associates

New Lung Associates is a pulmonary group of physicians leading the Lung Transplant Program and the Adult Cystic Fibrosis Program at Tampa General Hospital, a 988-bed acute care ho...

Cystic Fibrosis Foundation, Northern Ohio Chapter

The Northern Ohio Chapter of the Cystic Fibrosis Foundation works to help develop a means to control and cure cystic fibrosis and to improve the lives of those with the dis...

More Information about "The Pulmonary Fibrosis Foundation" on BioPortfolio

We have published hundreds of The Pulmonary Fibrosis Foundation news stories on BioPortfolio along with dozens of The Pulmonary Fibrosis Foundation Clinical Trials and PubMed Articles about The Pulmonary Fibrosis Foundation for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of The Pulmonary Fibrosis Foundation Companies in our database. You can also find out about relevant The Pulmonary Fibrosis Foundation Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Pulmonary
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...


Corporate Database Quicklinks



Searches Linking to this Company Record